



US009243025B2

(12) **United States Patent**  
Surleraux et al.

(10) **Patent No.:** US 9,243,025 B2  
(45) **Date of Patent:** Jan. 26, 2016

(54) **COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS**

(75) Inventors: **Dominique Surleraux**, Wauthier-Braine (BE); **Gilles Gosselin**, Montpellier (FR)

(73) Assignee: **Idenix Pharmaceuticals, LLC**, Cambridge, MA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 662 days.

(21) Appl. No.: **13/436,587**

(22) Filed: **Mar. 30, 2012**

(65) **Prior Publication Data**

US 2012/0251487 A1 Oct. 4, 2012

**Related U.S. Application Data**

(60) Provisional application No. 61/470,334, filed on Mar. 31, 2011.

(51) **Int. Cl.**

**A01N 43/04** (2006.01)  
**A61K 31/70** (2006.01)  
**C07H 21/02** (2006.01)  
**A61K 31/706** (2006.01)  
**A61K 31/7076** (2006.01)  
**A61K 31/7052** (2006.01)  
**A61K 31/7064** (2006.01)  
**A61K 31/7042** (2006.01)  
**A61K 31/708** (2006.01)  
**C07H 19/167** (2006.01)  
**C07H 19/20** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C07H 21/02** (2013.01); **A61K 31/706** (2013.01); **A61K 31/708** (2013.01); **A61K 31/7042** (2013.01); **A61K 31/7052** (2013.01); **A61K 31/7064** (2013.01); **A61K 31/7076** (2013.01); **C07H 19/167** (2013.01); **C07H 19/20** (2013.01)

(58) **Field of Classification Search**

None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,480,613 A 11/1969 Walton  
3,536,809 A 10/1970 Applezweig  
3,598,123 A 8/1971 Zaffaroni  
3,845,770 A 11/1974 Theeuwes et al.  
3,916,899 A 11/1975 Theeuwes et al.  
4,008,719 A 2/1977 Theeuwes et al.  
5,026,687 A 6/1991 Yarchoan et al.  
5,059,595 A 10/1991 Le Grazie et al.  
5,073,543 A 12/1991 Marshall et al.  
5,118,672 A 6/1992 Schinazi et al.  
5,120,548 A 6/1992 McClelland et al.  
5,149,794 A 9/1992 Yatvin et al.  
5,354,556 A 10/1994 Sparks et al.

5,455,339 A 10/1995 Chu et al.  
5,496,546 A 3/1996 Wang et al.  
5,538,865 A 7/1996 Reyes et al.  
5,591,767 A 1/1997 Mohr et al.  
5,610,054 A 3/1997 Draper et al.  
5,627,185 A 5/1997 Gosselin et al.  
5,633,358 A 5/1997 Gruetzke et al.  
5,639,476 A 6/1997 Oshlack et al.  
5,639,480 A 6/1997 Bodmer et al.  
5,674,533 A 10/1997 Santus et al.  
5,725,859 A 3/1998 Omer et al.  
5,733,566 A 3/1998 Lewis et al.  
5,739,108 A 4/1998 Mitchell  
5,830,905 A 11/1998 Diana et al.  
5,837,257 A 11/1998 Tsai et al.  
5,846,964 A 12/1998 Ozeki et al.  
5,869,253 A 2/1999 Draper et al.  
5,891,474 A 4/1999 Busetti et al.  
5,891,874 A 4/1999 Colacino et al.  
5,922,356 A 7/1999 Koseki et al.  
5,922,757 A 7/1999 Chojkier et al.  
5,972,891 A 10/1999 Kamei et al.  
5,980,945 A 11/1999 Ruiz et al.  
5,981,247 A 11/1999 Hagedorn et al.  
5,990,276 A 11/1999 Zhang et al.  
5,993,855 A 11/1999 Yoshimoto et al.  
6,004,933 A 12/1999 Spruce et al.  
6,034,134 A 3/2000 Gold et al.  
6,043,077 A 3/2000 Barber et al.  
6,045,830 A 4/2000 Igari et al.  
6,056,961 A 5/2000 Lavie et al.  
6,071,922 A 6/2000 Schinazi et al.  
6,087,324 A 7/2000 Igari et al.  
6,113,943 A 9/2000 Okada et al.  
6,174,868 B1 1/2001 Anderson et al.  
6,197,350 B1 3/2001 Yamagata et al.  
6,248,363 B1 6/2001 Patel et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1133642 C 1/2004  
CN 101333235 A 12/2008

(Continued)

OTHER PUBLICATIONS

Reddy et al. *Der Pharma Chemica* (2010), vol. 2, pp. 1-9.\*  
Egron et al. *J. Med. Chem.* (2003), vol. 46, pp. 4564-4571.\*  
Sofia et al. *J. Med. Chem.* (2010), vol. 53, pp. 7202-7218.\*  
Bobeck et al. *Antiviral Therapy* (2010), vol. 15, pp. 935-950.\*  
U.S. Appl. No. 10/608,907, filed Jun. 27, 2003, Sommadossi.  
U.S. Appl. No. 11/854,218, filed Sep. 12, 2007, Clark.  
U.S. Appl. No. 12/131,868, filed Jun. 2, 2008, Sommadossi.

(Continued)

*Primary Examiner* — Patrick Lewis  
(74) *Attorney, Agent, or Firm* — Jones Day

(57) **ABSTRACT**

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

**60 Claims, No Drawings**